JP7689492B2 - 嚢胞性線維症を治療するためのアミノ酸組成物及び方法 - Google Patents

嚢胞性線維症を治療するためのアミノ酸組成物及び方法 Download PDF

Info

Publication number
JP7689492B2
JP7689492B2 JP2021523195A JP2021523195A JP7689492B2 JP 7689492 B2 JP7689492 B2 JP 7689492B2 JP 2021523195 A JP2021523195 A JP 2021523195A JP 2021523195 A JP2021523195 A JP 2021523195A JP 7689492 B2 JP7689492 B2 JP 7689492B2
Authority
JP
Japan
Prior art keywords
cftr
amino acids
free amino
amino acid
proline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506044A (ja
JP2022506044A5 (https=
Inventor
ヴィディアサガー，サダサイヴァン
グロシェ，アストリド
ス，シャオドン
リン，シャンシャン
プラバカラン，スリーカラ
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド filed Critical ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
Publication of JP2022506044A publication Critical patent/JP2022506044A/ja
Publication of JP2022506044A5 publication Critical patent/JP2022506044A5/ja
Priority to JP2025087837A priority Critical patent/JP2025128185A/ja
Application granted granted Critical
Publication of JP7689492B2 publication Critical patent/JP7689492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2021523195A 2018-10-30 2019-10-30 嚢胞性線維症を治療するためのアミノ酸組成物及び方法 Active JP7689492B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087837A JP2025128185A (ja) 2018-10-30 2025-05-27 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
US62/752,847 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087837A Division JP2025128185A (ja) 2018-10-30 2025-05-27 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022506044A JP2022506044A (ja) 2022-01-17
JP2022506044A5 JP2022506044A5 (https=) 2022-11-09
JP7689492B2 true JP7689492B2 (ja) 2025-06-06

Family

ID=70464502

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523195A Active JP7689492B2 (ja) 2018-10-30 2019-10-30 嚢胞性線維症を治療するためのアミノ酸組成物及び方法
JP2025087837A Pending JP2025128185A (ja) 2018-10-30 2025-05-27 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087837A Pending JP2025128185A (ja) 2018-10-30 2025-05-27 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法

Country Status (10)

Country Link
US (1) US12220400B2 (https=)
EP (1) EP3873453A4 (https=)
JP (2) JP7689492B2 (https=)
KR (1) KR20210086660A (https=)
CN (1) CN113164425A (https=)
AU (2) AU2019370363B2 (https=)
BR (1) BR112021008395A2 (https=)
CA (1) CA3116015A1 (https=)
MX (1) MX2021005113A (https=)
WO (1) WO2020092639A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177780A1 (en) * 2020-05-29 2021-12-02 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501068A (ja) 2001-08-08 2005-01-13 プロフェッショナル・ダイエテティクス・ソシエタ・ア・レスポンサビリタ・リミタータ 特に眼科分野における適用のための外傷および損傷の治癒および／または修復のための治療に適したアミノ酸組成物
WO2009051909A1 (en) 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
WO2009147637A1 (en) 2008-06-06 2009-12-10 Professional Dietetics S.R.L. Compositions comprising amino acids, with pro-angiogenic activity
WO2016191263A1 (en) 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
WO2017223188A1 (en) 2016-06-21 2017-12-28 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002098405A1 (fr) 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
WO2003055481A1 (en) 2001-12-25 2003-07-10 Ajinomoto Co., Inc. Organ fibrosis inhibitors
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1513870A4 (en) * 2002-05-31 2006-06-07 Childrens Hosp Medical Center CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL FOR TREATING MUCOVISCIDOSE AND TECHNIQUES AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THESE
AU2003901316A0 (en) * 2003-03-21 2003-04-03 The Royal Alexandra Hospital For Children Regulation of cell surface proteins
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
EP2664326B1 (en) 2012-05-17 2017-11-01 I.E.R.F.C. European Institute for Cystic Fibrosis Research Combined therapy for cystic fibrosis
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
CA3001099A1 (en) * 2015-10-09 2017-04-13 Abbvie S.A.R.L. Potentiator-corrector combinations useful in the treatment of cystic fibrosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501068A (ja) 2001-08-08 2005-01-13 プロフェッショナル・ダイエテティクス・ソシエタ・ア・レスポンサビリタ・リミタータ 特に眼科分野における適用のための外傷および損傷の治癒および／または修復のための治療に適したアミノ酸組成物
WO2009051909A1 (en) 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
WO2009147637A1 (en) 2008-06-06 2009-12-10 Professional Dietetics S.R.L. Compositions comprising amino acids, with pro-angiogenic activity
WO2016191263A1 (en) 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
WO2017223188A1 (en) 2016-06-21 2017-12-28 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
医薬品インタビューフォーム アミパレン輸液，改訂第７版，2012年

Also Published As

Publication number Publication date
AU2019370363A1 (en) 2021-05-13
JP2022506044A (ja) 2022-01-17
KR20210086660A (ko) 2021-07-08
AU2025248660A1 (en) 2025-10-30
BR112021008395A2 (pt) 2021-09-28
EP3873453A4 (en) 2022-08-03
US12220400B2 (en) 2025-02-11
CN113164425A (zh) 2021-07-23
JP2025128185A (ja) 2025-09-02
CA3116015A1 (en) 2020-05-07
MX2021005113A (es) 2021-06-15
US20210393584A1 (en) 2021-12-23
AU2019370363B2 (en) 2025-07-10
WO2020092639A1 (en) 2020-05-07
EP3873453A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
JP2025128185A (ja) 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法
Rotin et al. Function and regulation of the epithelial Na+ channel ENaC
TWI870336B (zh) 重組人類酸性α-葡萄糖苷酶
US20020115619A1 (en) Compositions and methods for treatment of cystic fibrosis
JP7482914B2 (ja) ホモシスチン尿症の治療する組成物および方法
JP6672139B2 (ja) 粘液の粘性の正常化のための組成物
WO2017147720A1 (en) Method for treating a central nervous system disorder
WO1996006612A1 (en) Method and composition for treating cystic fibrosis
WO2020115231A1 (en) Methods and compositions for treating cystic fibrosis airways
WO2019070759A1 (en) AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
Schwiebert et al. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein
US20070213261A1 (en) Asthma Preparation
JP2022517255A (ja) 上皮または内皮バリア機能の改善
Wu et al. CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways
IL290078B2 (en) Treatment of cystic fibrosis by administering mRNA encoding CFTR in the form of a fine spray
EP3452041B1 (en) Compositions and methods for administering ppar-gamma-agonists, surfactant peptides and phospholipids
WO2019070753A1 (en) AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA
JP7630540B2 (ja) 神経保護ペプチド
CN115916244A (zh) 用于治疗戊二酸尿症的组合物及其给药方法
US5834421A (en) Methods and compositions for treating cystic fibrosis
KR20250114044A (ko) 만성 호흡기 질환 치료약
Hildebrandt et al. Characterization of chronic nicotine exposure on the survival of the" spastic" Han-Wistar rat
WO2025111297A1 (en) Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
Kirjavainen et al. silencing the p27" expression, myosin VIla was labeled immuno

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250527

R150 Certificate of patent or registration of utility model

Ref document number: 7689492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150